For FY26, the company expects total research and development plus selling, general and administrative expenses to be approximately $400M, excluding the impact of $50M in estimated non-cash stock compensation expense. Syndax (SNDX) expects that its operating expense base will remain stable over the next couple of years. As a result, Syndax expects that its cash, cash equivalents and short-term investments, combined with its anticipated product revenue, collaboration revenue and interest income, will enable the company to reach profitability.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- SNDX Upcoming Earnings Report: What to Expect?
- Syndax price target raised to $28 from $27 at BofA
- Syndax’s Revumenib Solid-Tumor Trial Completion: What Investors Should Watch Next
- Syndax Pharmaceuticals: Strong Revuforj Momentum, Underappreciated Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
- Syndax: Strong Revuforj and Niktimvo Momentum Undervalues Commercial Trajectory and Pipeline Upside
